Fast Tracked New Reviews The process begins when a sponsor requests Fast Tracked status from the FDA, which can be done concurrently with an Investigational New Drug application or at any later point before the pre-NDA meeting; once the request is filed the FDA has approximately 60 days to decide whether the program merits Fast Tracked, and if approved the mechanics of Fast Tracked — more frequent meetings, enhanced written interactions, and the rolling review option — come into play. Operationally, the rolling review mechanism central to Fast Tracked means that the FDA allocates review resources to completed portions of an NDA or BLA as those sections arrive, enabling reviewers to begin assessing efficacy, safety, and manufacturing modules while other pieces are still under preparation, and this staggered review changes the critical path for approval timelines. The Fast Tracked pathway also includes ongoing compliance: the sponsor must continue to meet the original qualifying criteria — that the drug addresses a serious condition and shows potential to address an unmet need — and the FDA retains the authority to rescind Fast Tracked status if later data no longer supports these claims. Practically, Fast Tracked also affects internal sponsor behavior: teams reorganize timelines to prepare for rolling submissions, prioritize data analyses that will be most persuasive to reviewers, and plan potential confirmatory trials in parallel when Accelerated Approval is a possible outcome, which makes Fast Tracked a planning tool as much as a regulatory label.
Fast Tracked New Reviews Fast Tracked is designed for drug developers — pharmaceutical and biotechnology companies of all sizes — who are developing therapies for serious or life-threatening conditions where existing treatments are inadequate or absent; sponsors working on oncology agents, rare disease therapies, treatments for degenerative neurologic diseases like Alzheimer's, novel antivirals for serious infections, or medications for advanced heart failure commonly seek Fast Tracked because these conditions meet the seriousness and unmet need thresholds the FDA uses to evaluate requests. Fast Tracked is not intended for drugs targeting minor or non-serious indications; if a product addresses a condition that does not substantially affect daily functioning or survival, the Fast Tracked criteria will not be satisfied and the designation is not appropriate. Sponsor teams should also consider Fast Tracked when they have mechanistic rationale or early nonclinical or clinical data suggesting the product could fill an unmet need, because Fast Tracked can be requested earlier in development than Breakthrough Therapy designation which generally demands preliminary clinical evidence of substantial improvement. Operationally, development programs that lack the infrastructure to coordinate rolling submissions and frequent regulator interactions may find the administrative demands of Fast Tracked challenging; teams must be prepared to marshal cross-functional resources, produce quality modules on a compressed cadence, and engage in substantive regulatory dialogue, which is why Fast Tracked is best for sponsors willing to invest in an accelerated development model. Order Now Fast Tracked Reviews and Complaints BBB